Inventages Venture Capital Investment Inc.
VC Fund
London, United Kingdom
Inventages Venture Capital Investment Inc. is a VC fund in London focused on Biotechnology and Health Care. Inventages Venture Capital Investment Inc is an investment arm of Nestle SA specializing in PIPES, seed, early, mid, and late venture investments. The firm seeks to invest in middle market and mature companies. It provides mezzanine and bridge financing. The firm seeks to invest in health care, life sciences, cosmeceuticals, pharmaceuticals,enabling technologies and services, and diagnostic and medical devices. Within the pharmaceutical sector, it typically invests in small molecules, proteins, antibodies, vaccines, phytopharmaceuticals, natural compounds, botanicals, antibiotics, and therapeutics. Within the diagnostic sector, it focuses on genetic materials, biomarkers, pathological markers, genetic profiles, protein profiles, pharmacogenomics, food and environmental safety, genetically modified organism detection and trading, medical monitoring, diagnostic and analytical tools, and quality control. Within enabling technologies and services it primarily invests in novel packaging, process and production technologies, supply chain management, innovative materials and resources, delivery systems for active compounds, encapsulation and prevention, food services, extraction and fractionation of biological materials, consumer relation management, green biotechnology, smell and taste modifying technologies, genomics, proteomics, metabolomics, screen and characterization technologies, chemical and biological engineering, and innovative preventive and therapeutic concepts. It also invests in companies involved in the prevention of medical foods, nutraceuticals, cosmoceuticals, nutrition, innovative food, functional food, dietary and food supplements, oral and skin care, immune modulation and stimulation, and health and disease management.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 65%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Inventages Venture Capital Investment Inc. invests in
Stages Inventages Venture Capital Investment Inc. invests in
Countries Inventages Venture Capital Investment Inc. invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 15 (41%)
- Health Care 9 (24%)
- Therapeutics 7 (19%)
- Pharmaceutical 6 (16%)
- Medical 5 (14%)
Stage
- Series A 11 (30%)
- Series B 9 (24%)
- Funding Round 7 (19%)
- Series D 3 (8%)
- Series C 2 (5%)
Country
- United States 12 (32%)
- United Kingdom 4 (11%)
- Canada 2 (5%)
- Germany 2 (5%)
- The Netherlands 2 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Ashok Dhanrajgir
Senior Vice President
|
Senior Vice President | Total investments: 2 | Find email | |
Hervé Girsault
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Bill Kermode
Partner
|
Partner | Total investments: 0 | Find email | |
Erich Sieber
Senior Vice President
|
Senior Vice President | Total investments: 2 | Find email | |
François Struye de Swielande
Senior Vice President
|
Senior Vice President | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ripple Foods
|
Ripple Foods specializes in making non-dairy milk with just as much protein as milk and half the sugar. Ripple has 8x the protein of almond milk and half the sugar of dairy milk. It’s high in bioavailable calcium (50% more than milk), potassium and provides a good source of omega-3s. It’s lower in calories than milk and best of all, it has thecreamy, delicious texture our dairy-free friends are missing. No more thin, chalky almond/ soy/ cashew milk.It was founded in 2014 and headquartered in Emeryville, California. | $55.8M / Series D / Oct 22, 2020 | |
Accera
|
Accera is a biotechnology company that engages in the discovery and development of therapeutic drugs for neurodegenerative diseases. It offers Ketasyn, a molecule for Alzheimer's, Parkinson's, and age-associated memory impairment. It was founded in 2001 and is headquartered in Broomfield, Colorado. | $50M / Oct 04, 2018 | |
XOLUTION
|
XOLUTION is the most advanced reclosable beverage container solution. Already in its prototype state, the new XO resealable can won the Can of the Year Award in Dubai in 2009 (Winner Silver - Category Prototype) and was enhanced and refined since, involving extensive market research and field testing. With the can now entering the consumer beveragemarket, they are confident that the product resembles a step forward for XOLUTION in becoming the market leader in this field. XOLUTION GmbH is headquartered in Munich, Germany. In 2008, Marc von Rettberg was named Chief Executive of the company. He joined Christian Bratsch, Vice President R&D, to introduce innovative designs to the beverage packaging industry for reclosable beverage cans.Rettberg and Bratsch established new product design guidelines with a clear focus on values and benefits for the entire supply chain. The innovative beverage can ends were required to offer easy usage to the consumer (intuitive, easy to open and reseal), easy integration for the beverage filler in the existing processes (no major adjustments to the filling line), easy handling for the can maker (XO reclosable can ends based on standard shells), and improved commercialization for the beverage brand (unique branding options). And, of course, the focus was set on providing these benefits at a reasonable overall cost.In 2009, Can Maker Magazine recognized the XOLUTION innovative resealable can with the Silver Award in the Prototype category for the XO-400 reclosable beverage can lid. Since Time-to-Market is a key challenge for all innovators, Rettberg and Bratsch have created a competitive advantage of rapid prototyping and testing capabilities in their Salzburg R&D Center. XOLUTION GmbH is managed by one of the most competent teams in the business. With long-term experiences in their respective fields, their leading specialists guarantee the best coverage of all business areas from prototyping, R&D and product management to trading and distribution. With their knowledge, the XO Resealable Can was successfully converted from a simple vision to a technologically sophisticated product that will have a significant influence on the canned beverage market. | $49.4M / Jan 11, 2016 | |
Cognoptix
|
Cognoptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer's Disease. Cognoptix's goal is to provide clinicians with a quick, predictive, reliable, inexpensive, and widely available test, enabling early diagnosis and treatment.The company was founded in 2001 and headquarteredin Marlborough, Massachusetts. | $15M / Series D / Sep 30, 2014 | |
AM Pharma
|
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands. | $13.4M / Series E / Sep 11, 2014 | |
Phagenesis
|
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $17M / Series B / May 22, 2013 | |
Phosphate Therapeutics
|
Phosphate Therapeutics, a UK-based independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals. The company intends to use the capital to complete the Phase 2 development of its phosphate binder (PT20) for the treatment of a late-stage renal disease suffer from systemic phosphate accumulation,hyperphosphataemia, whose global rights were acquired from the Medical Research Council. | $11.5M / Mar 05, 2012 | |
|
Phagenesis
|
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology. | $7.7M / Series B / Oct 04, 2011 | |
MSI Methylation Sciences
|
MSI Methylation Sciences Inc. operates as a biotechnology company. The company develops and markets S-Adenosyl Methionine, a prescription drug used as a dietary supplement. MSI Methylation Sciences Inc. was founded in 2007 and is based in West Vancouver, Canada. | $14.8M / Series A / Sep 29, 2011 | |
Shield Therapeutics
|
Shield Therapeutics is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need. During 2011 Shield will be commencing global pivotal Phase III studies of its lead asset, ST10-021, for the treatment of irondeficiency anaemia associated with inflammatory bowel disease and subsequently chronic kidney disease. The Company is headquartered in Wollerau, Switzerland. | $9M / Series A / Jun 01, 2011 | |
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Inventages Venture Capital Investment Inc. invest in?
Inventages Venture Capital Investment Inc. invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Inventages Venture Capital Investment Inc.?
Public channels for Inventages Venture Capital Investment Inc. include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Inventages Venture Capital Investment Inc.?
The team at Inventages Venture Capital Investment Inc. includes Ashok Dhanrajgir (Senior Vice President), Hervé Girsault (Venture Partner) and Bill Kermode (Partner), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
